\begin{longtable}{lcccccc}
\caption{Inference for Day 18antibody marker covariate-adjusted correlates of risk of HPV pooled over treatment groups: Odds ratios per SD increment in the marker*} \\ 
   \hline
 
         \multicolumn{1}{l}{IARC HPV} & \multicolumn{1}{c}{No. cases /}   & \multicolumn{2}{c}{OR per SD incr.}                     & \multicolumn{1}{c}{P-value}   & \multicolumn{1}{c}{q-value}   & \multicolumn{1}{c}{FWER} \\ 
         \multicolumn{1}{l}{Immunologic Marker}            & \multicolumn{1}{c}{No. at-risk**} & \multicolumn{1}{c}{Pt. Est.} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{(2-sided)} & \multicolumn{1}{c}{***} & \multicolumn{1}{c}{} \\ 
         \hline
 
    Anti L1, L2 IgG HPV6 (AU/ml) & 26/3,023 & 0.83 & (0.57-1.22) & 0.340 & 0.810 & 1.000 \\ 
  Anti L1, L2 IgG HPV11 (AU/ml) & 26/3,023 & 0.93 & (0.64-1.36) & 0.724 & 0.810 & 1.000 \\ 
  Anti L1, L2 IgG HPV16 (IU/ml) & 26/3,023 & 0.91 & (0.61-1.34) & 0.626 & 0.810 & 1.000 \\ 
  Anti L1, L2 IgG HPV18 (IU/ml) & 26/3,023 & 0.70 & (0.49-1.00) & 0.052 & 0.405 & 0.525 \\ 
  Anti L1, L2 IgG HPV31 (AU/ml) & 26/3,023 & 1.16 & (0.77-1.75) & 0.465 & 0.810 & 1.000 \\ 
  Anti L1, L2 IgG HPV33 (AU/ml) & 26/3,023 & 1.08 & (0.78-1.50) & 0.655 &     &     \\ 
  Anti L1, L2 IgG HPV45 (AU/ml) & 26/3,023 & 0.74 & (0.43-1.28) & 0.281 &     &     \\ 
  Anti L1, L2 IgG HPV52 (AU/ml) & 26/3,023 & 1.08 & (0.72-1.63) & 0.702 &     &     \\ 
  Anti L1, L2 IgG HPV58 (AU/ml) & 26/3,023 & 1.05 & (0.75-1.47) & 0.766 &     &     \\ 
  Anti L1, L2 IgG Score & 26/3,023 & 0.92 & (0.60-1.39) & 0.687 &     &     \\ 
   \hline
\hline
\label{tab:CoR_univariable_logistic_pretty_scaled}
\end{longtable}
